Breast Cancer Research and Treatment **32**: 335, 1994.
© 1994 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 32

Alama A 311
Allred DC 5,13,,39
Arndt D 269
Asongwe G 269
Aubert JP 139
Axelsson CK 281

Baker WJ 57
Baldini E 311
Balslev I 281
Bame PD 319
Barbieri F 311
Ben-Ezra J 261
Benedix M 177
Berois N 139
Bezwoda WR 229
Bibby MC 269
Blijham GH 197
Borochovitz D 327
Bozzetti C 221

Calvo F 139
Camisa R 221
Camoriano A 311
Campora E 311
Carstensen B 281
Chamness GC 1,177
Chen G 19
Clark GM 105
Cocconi G 221
Conte PF 311
Coutts A 153
Cox LA 19

Davis PL 327
de Jong J 197
De Cremoux P 139
De Laurentiis M 105,113
DeGregorio MW 57
Diamandis EP 291,301
Dickson RB 239
Double JA 269

Eckardt J 67
Elbe B 187
Elledge RM 39

Fenichel P 213
Fichtner I 187,269
Floyd LJ 119
Fuqua SAW 5,13,49,67,177

Gardin G 311
Giannessi PG 311
Gnant MFX 165
Grass L 291
Guazzi A 221

Haensch W 187
Harris KB 327
Hilsenbeck SG 67,105
Hofman P 213
Holdaway IM 203
Howes L 97
Hsi B-L 213
Hupperets PS 197

Jager J 197
Jakesz R 165
Julian TB 327
Jungmann S 269

Kay RG 203
Klementaviciene J 327
Koehler RE 57
Koester SK 57
Krieg S 177
Kummer A 165

Lee EY-HP 19
LeMaistre CF 97

Maemura M 239
Maenpaa JU 57
Manie S 213
Manotti L 221
Mason BH 203
McCarty KS Jr 327
Meazza R 311
Meneghetti C 97
Merlini L 311
Mistro D 139
Mittlböck M 165
Mouridsen H 281
Mundy GR 73
Murphy LC 153
Murphy LJ 153

Naldi N 221
Naso C 311
Naundorf H 187,269
Neumayer R 165
Nizzoli R 221

O'Connell P 5,13
Odom-Maryon T 261
Oesterreich S 67,177
Ollom CM 119
Orang-Khadivi K 119
Osborne CK 1,5,13,39,49,67,97,105
Osinaga E 139

Pancino G 139
Pekkel V 5
Pezner RD 261
Pierce BL 119
Porchet N 139
Pronzatto P 311

Rasmussen BB 281
Ravdin PM 105,113
Reinecke S 187
Reiner A 165
Reiner G 165
Repetto L 311
Retsky MW 319
Roseto A 139
Rossi B 213
Rosso R 311
Rudas M 165

Sasaki A 73
Saul G-J 187
Savoldi L 221
Schouten LJ 197
Schutte B 197
Seymour L 229
Siegle RL 119
Skinner SJM 203
Staiger M 327
Sutherland DJA 301
Swartzendruber DE 319

Thyss A 213

van Assche C 197
Von Hoff DD 67

Wagman LD 261
Wardwell RH 319
Weng C-N 177
Wiebe VJ 57
Williams RF 119
Wurz GT 57

Yee D 85
Yoneda T 73
Yu H 291,301

Zarghami N 291
Zedeler K 281
Zeisig R 269
Zschiesche W 187

Breast Cancer Research and Treatment **32**: 335, 1994.
© 1994 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 32

Alama A 311
Allred DC 5,13,,39
Arndt D 269
Asongwe G 269
Aubert JP 139
Axelsson CK 281

Baker WJ 57
Baldini E 311
Balslev I 281
Bame PD 319
Barbieri F 311
Ben-Ezra J 261
Benedix M 177
Berois N 139
Bezwoda WR 229
Bibby MC 269
Blijham GH 197
Borochovitz D 327
Bozzetti C 221

Calvo F 139
Camisa R 221
Camoriano A 311
Campora E 311
Carstensen B 281
Chamness GC 1,177
Chen G 19
Clark GM 105
Cocconi G 221
Conte PF 311
Coutts A 153
Cox LA 19

Davis PL 327
de Jong J 197
De Cremoux P 139
De Laurentiis M 105,113
DeGregorio MW 57
Diamandis EP 291,301
Dickson RB 239
Double JA 269

Eckardt J 67
Elbe B 187
Elledge RM 39

Fenichel P 213
Fichtner I 187,269
Floyd LJ 119
Fuqua SAW 5,13,49,67,177

Gardin G 311
Giannessi PG 311
Gnant MFX 165
Grass L 291
Guazzi A 221

Haensch W 187
Harris KB 327
Hilsenbeck SG 67,105
Hofman P 213
Holdaway IM 203
Howes L 97
Hsi B-L 213
Hupperets PS 197

Jager J 197
Jakesz R 165
Julian TB 327
Jungmann S 269

Kay RG 203
Klementaviciene J 327
Koehler RE 57
Koester SK 57
Krieg S 177
Kummer A 165

Lee EY-HP 19
LeMaistre CF 97

Maemura M 239
Maenpaa JU 57
Manie S 213
Manotti L 221
Mason BH 203
McCarty KS Jr 327
Meazza R 311
Meneghetti C 97
Merlini L 311
Mistro D 139
Mittlböck M 165
Mouridsen H 281
Mundy GR 73
Murphy LC 153
Murphy LJ 153

Naldi N 221
Naso C 311
Naundorf H 187,269
Neumayer R 165
Nizzoli R 221

O'Connell P 5,13
Odom-Maryon T 261
Oesterreich S 67,177
Ollom CM 119
Orang-Khadivi K 119
Osborne CK 1,5,13,39,49,67,97,105
Osinaga E 139

Pancino G 139
Pekkel V 5
Pezner RD 261
Pierce BL 119
Porchet N 139
Pronzatto P 311

Rasmussen BB 281
Ravdin PM 105,113
Reinecke S 187
Reiner A 165
Reiner G 165
Repetto L 311
Retsky MW 319
Roseto A 139
Rossi B 213
Rosso R 311
Rudas M 165

Sasaki A 73
Saul G-J 187
Savoldi L 221
Schouten LJ 197
Schutte B 197
Seymour L 229
Siegle RL 119
Skinner SJM 203
Staiger M 327
Sutherland DJA 301
Swartzendruber DE 319

Thyss A 213

van Assche C 197
Von Hoff DD 67

Wagman LD 261
Wardwell RH 319
Weng C-N 177
Wiebe VJ 57
Williams RF 119
Wurz GT 57

Yee D 85
Yoneda T 73
Yu H 291,301

Zarghami N 291
Zedeler K 281
Zeisig R 269
Zschiesche W 187

Breast Cancer Research and Treatment **32**: 337-341, 1994.
© 1994 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 32

adhesion molecules
in osteolytic bone metastasis 73-84
involvement in metastasis — review 239-260
adjuvant chemotherapy
abstracts S37-S38
alkylphosphocholines
antitumor activity in ER-negative tumors 269-279
androgens
low urine and plasma levels and poor prognosis 203-212
angiogenesis
abstracts S60
animal models
of bone metastasis 73-84
of tamoxifen resistance 49-55
two new human breast cancer lines in nude mice — preclinical drug testing 187-196
antiestrogens
pure steroidal, in overcoming tamoxifen resistance 49-55
regulation of IGF binding proteins 153-164
antigens
Tn-related tumor-associated acidic glycoprotein 139-152
atypical ductal hyperplasia
see premalignant breast disease
autocrine growth factors
the IGF system as a target for therapy 85-95
axillary dissection
abstracts S39-S41
cost-effectiveness S92
axillary lymph nodes
improved microstaging S94

benign breast disease
see also premalignant breast disease
bisphosphonates
against bone metastases 73-84
bone marrow support
with high-dose chemotherapy — abstracts S63-S66
bone metastasis
cytokines, osteoclasts, and cell adhesion molecules 73-84
enhanced by parathyroid hormone related protein (PTHrP) S91
nude mouse model 73-84
breast cancer cell lines
two new human lines in nude mice — preclinical drug testing 187-196
breast conservation
abstracts S41-S42
with clear margins — radiation therapy without local boost 261-267

cadherins
in osteolytic bone metastasis 73-84
involvement in metastasis — review 239-260
cell adhesion molecules
see adhesion molecules
cell biology
abstracts S78-S83
chemotherapy
abstracts S62-S66,S93
alkylphosphocholines — activity in ER-negative tumors 269-279
for advanced disease — abstracts S33-S37
primary — enhanced effectiveness in high TLI group 311-318
clonal progression
premalignant and associated invasive breast disease 5-12
complement regulatory proteins
high CD46 (and absent CD55) in malignant breast cells 213-219
computer modeling
Gompertzian vs. stochastic growth — predictions for treatment 319-325
correspondence analysis
in integration of prognostic factor data 105-112
cost-effectiveness
abstracts S73-S74
of axillary dissection S92

Cox proportional hazards model
in integration of prognostic factor data 105-112
cytokines
abstracts S54-S57

detection
by surface electropotential evaluation S92
detection and diagnosis
abstracts S86-S87
diet
abstracts S90
doxorubicin
enhanced dose response with erbB-2 overexpression S32
resistance induced by hsp27 67-71
drug resistance
abstracts S38-S39
and heat shock proteins 67-71
partial reversal by protein kinase C pseudosubstrates S31
resensitization by toremifene 57-65
ductal carcinoma in situ (DCIS)
abstracts S43-S44
clonal relationship of breast cancer progression stages 5-12
histologic prediction of recurrence S32
recapitulation in nodal metastases S33

endocrine therapy
abstracts S67-S69
endothelial cells
interactions with cell adhesion molecules in breast cancer metastasis 239-260
epidermal growth factor (EGF) receptor
targeted therapy with an EGF ligand fusion toxin 97-103
erbB receptor family and ligands
and biological behavior S93
erbB-2 oncogene
overexpression during breast cancer evolution, especially comedo DCIS 13-18
estrogen receptor
novel 80 kDa ER-related protein S94
point mutation and tamoxifen resistance S32
variants in tamoxifen resistance 53-54
evolution of breast cancer
clonal relationship of malignant and "premalignant" lesions 5-12
evolution of breast cancer (cont.)
immunohistochemical markers of progression stages 13-18
increased complement regulatory protein CD46 with increased malignancy 213-219

fine needle aspiration
for multiple immunocytochemical assays of breast tumors 221-228
flow cytometry
abstracts S53-S54
in monitoring drug effects 57-65
ploidy and S-phase in primary tumors vs. their nodal metastases 197-202

genetics
abstracts S75-S77
frequent deletion of the CDK4 inhibitor gene INK4 S92
linkage analysis of candidate loci S29
glycoproteins
Tn-related tumor-associated antigen 139-152
growth factors
abstracts S54-S57
growth fraction
TLI vs Ki67 — comparison and prognostic values 165-175
growth kinetics
Gompertzian vs. stochastic models — predictions for treatment 319-325

heat shock proteins
constitutive overexpression of hsp27 in late passage breast cancer cells 177-186
hsp27 and doxorubicin resistance 67-71
hsp70 in prognosis 67-71
heat shock transcription factors
and loss of estrogen and heat regulation of hsp27 in late passage cells 177-186
HER-2/neu
see erbB-2
high-dose chemotherapy
with marrow support — abstracts S63-S66
histologic grade
in Nottingham Prognostic Index applied to Danish patients 281-290
hyperplasia
see premalignant breast disease

imaging
gadolinium-melanin polymer MRI contrast agents targeted to breast cancer 119-135
immunocytochemistry
multiple assays in fine needle aspirates 221-228
immunology
high CD46 and absent CD55 in malignant breast cells 213-219
immunotherapy
and immunology — abstracts S61-S62
anti-erbB-2 antibodies S30,S31
immunotoxins
and ligand fusion toxins in targeted therapy 97-103
insulin-like growth factors (IGFs)
and binding proteins, as targets for therapy 85-95
binding proteins regulated by antiestrogens and progestins 153-164
paracrine function of IGF-II S91
integrins
involvement in metastasis — review 239-260

Ki67 growth fraction
comparison with TLI in prognosis 165-175
in fine needle aspirates 221-228
kinetics of breast tumor growth
Gompertzian vs. stochastic models — predictions for treatment 319-325

laminins
involvement in metastasis — review 239-260
in osteolytic bone metastasis 73-84
ligand fusion toxins
EGF/diphtheria toxin — preclinical and clinical studies 97-103
liposomes
in reducing toxicity of alkylphosphocholines 269-279
loss of heterozygosity
in analyzing clonal relationship of malignant and "premalignant" lesions 5-12
in identifying tumor suppressor genes 19-38

magnetic resonance imaging (MRI)
detection and wire localization of an occult breast cancer 327-330
magnetic resonance imaging (MRI) (cont.)
gadolinium-melanin polymer contrast agents targeted to breast cancer 119-135
male breast cancer
abstracts S90-S91
mammography
and screening — abstracts S84-S86
cost-effectiveness targets S30
markers
abstracts S87-S89
marrow support
G-CSF S93
matrix metalloproteinases
in osteolytic bone metastasis 73-84
MCF-7 cells
and targeted therapy with IGF binding proteins 85-95
constitutive overexpression of hsp27 in late passage cells 177-186
prostate specific antigen induction by steroids (except estrogen) 291-300
metastasis
abstracts S83-S84
bone — cytokines, osteoclasts, and cell adhesion molecules 73-84
involvement of cell adhesion molecules — review 239-260
ploidy and S-phase in primary tumors vs. their nodal metastases 197-202
microdissection
in analyzing clonal relationship of malignant and "premalignant" lesions 5-12
molecular biology
abstracts S75-S77
monoclonal antibodies
323/A3 in targeted MRI contrast agent 119-135
83D4 against tumor-associated Tn-related epitope 139-152
mucins
compared with acidic tumor-associated Tn-related antigen 139-152

neoadjuvant chemotherapy
abstracts S62-S63
neural networks
in integration of prognostic factor data 105-112,113-118

nm23
review of tumor suppressor genes in breast cancer 28-29
Nottingham Prognostic Index
applied to 9149 Danish patients 281-290

occult breast cancer
detection and wire localization 327-330
oncogenes
and tumor suppressor genes — abstracts S74-S75
bcl-2 regulation by estrogens S31
osteoclasts
role in osteolytic bone metastases 73-84

p53
in breast cancer prognosis and response to therapy 39-47
overexpression during breast cancer evolution, especially comedo DCIS 13-18
review of tumor suppressor genes in breast cancer 23-25
p53 protein
in fine needle aspirates 221-228
paracrine interactions
new human breast cancer line in nude mice — stromal dependence 187-196
patient management issues
abstracts S71-S73
phosphocholines, alkyl
antitumor activity in ER-negative tumors 269-279
platelet derived growth factor (PDGF)
an adverse prognostic factor 229-233
ploidy
in primary tumors vs. their nodal metastases 197-202
polyamine biosynthesis inhibitors
therapeutic effects S94
premalignant breast disease
clonal relationship with later invasive lesion 5-12
immunohistochemical markers of progression stages 13-18
molecular genetics S29
progestins
regulation of IGF binding proteins 153-164
prognostic factors
abstracts S46-S54
gene alterations S92
heat shock protein hsp70 67-71
low urine and plasma androgens and poor survival 203-212
methods for integration 105-112,113-118
Nottingham Prognostic Index applied to Danish patients 281-290
p53 41-44
platelet derived growth factor — an adverse predictor 229-233
prostate specific antigen vs. ER, PgR, p53 301-310
TLI vs Ki67 growth fractions 165-175
uPA, PAI-1, and cathepsin D S29,S30
proliferative rate
TLI vs Ki67 — comparison and prognostic values 165-175
prostate specific antigen (PSA)
in 29% of breast tumor extracts 301-310
induction by steroids (except estrogen) in breast cancer cell lines 291-300
proteases
as prognostic factors — abstracts S51
psychological and social aspects of breast cancer
abstracts S44-S46

radiation therapy
abstracts S42-S43
without local boost, in conservative surgery with clear margins 261-267
recursive partitioning
in integration of prognostic factor data 105-112
retinoblastoma (*rb*) gene
review of tumor suppressor genes in breast cancer 20-23
retinoids
altered gene expression and inhibition of estrogen trans-activation S94
risk factors
abstracts S89-S90

S-phase
in primary tumors vs. their nodal metastases 197-202
see also proliferative rate, thymidine labeling, Ki67

San Antonio Breast Cancer Symposium
1994 abstracts S29-S94
1994 program S3-S28
screening
and mammography — abstracts S84-S86
signal transduction
interference by inhibiting AP-1 S91
special issues
San Antonio breast cancer SPORE 1-135
SPOREs in breast cancer
San Antonio translational research 1-135
statistical methods
for integration of prognostic factor data 105-112,113-118
stress response
see heat shock proteins
stromal interactions
new human breast cancer line in nude mice — stromal dependence 187-196
surgery
abstracts — S69-S71
axillary dissection — abstracts S39-S41
breast conservation with clear margins — radiation therapy 261-267
breast conservation — abstracts S41-S42
lumpectomy margin status and breast conservation S30

T47-D cells
IGF binding proteins regulated by antiestrogens and progestins 153-164
T47-D cells (cont.)
prostate specific antigen induction by steroids (except estrogen) 291-300
tamoxifen
effects and compliance monitored by flow cytometry 57-65
mechanisms of resistance 49-55
prevention trial — gynecologic assessment S29
tamoxifen resistance
ER mutation; ER, PgR, pS2 expression changes S32
targeted therapy
EGF/diphtheria toxin studies 97-103
IGF binding proteins 97-103
thymidine labeling index (TLI)
comparison with Ki67 growth fraction in prognosis 165-175
effect of primary chemotherapy, vs. tumor response and relapse rate 311-318
Tn antigen
related epitope associated with tumor cells 139-152
toremifene
resensitizing drug-resistant cells 57-65
translational research in breast cancer
San Antonio SPORE overview 1-4
tumor biology
abstracts S57-S60
tumor suppressor genes
abstracts S74-S75
review of roles in breast cancer 19-38
see also p53, retinoblastoma, etc.